Impact Factor
2.67
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
1.24
293 total citations
h5-index
20
h5 depth signal
Cited share
52.2%
128 of 245
Total citations
293
Citation footprint
Metric signal
0.90
External metric anchor
Self-citation
18.1%
53 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
971
China
354
Romania
149
Pakistan
105
Turkey
74
Citing Fields of Research
Cardiology
386
Hematology
190
Pharmacology & Toxicology
186
Psychiatry
134
Anesthetic & Pain Medicine
134
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
4,350
Articles tracked across the journal lifetime
Indexed publication set
245
128 cited publications
Last 12 months
223
18.6 publications/month
Open access share
2.7%
6 OA publications in the last year
Leading citing country
United States
971 citing publications
Leading citing field
Cardiology
386 citing publications
Latest tracked publication
20 October 2026
10 recent records available
Coverage & Indexing History
v4n1, Jan. 1997-
v4n1, Jan. 1997-
Active Coverage
Research Focus & Classification
Indexed Subjects
Cardiology
Psychiatry
Diabetes
Anesthetic & Pain Medicine
Hematology
Antibiotic & Antibacterial Agents
Broad Categories
Therapeutics
Musculoskeletal Disorders
Sports Science
Cardiology
Hematology
MeSH Descriptors
Therapeutics
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1097/mjt.0000000000002243
Open DOI
Off-Label Use of Monoclonal Antibodies in Developing Countries
Rituximab is used in different hematologic, rheumatic, neurologic, and renal disorders. As the clinical applications of this agent continue to expand, its use, including off-label use, requires careful and consistent evaluation. Off-labe...
02
03
04
DOI 10.1097/mjt.0000000000002250
Open DOI
Meta-Analysis of Long-Term Major Adverse Cardiovascular Events of Different Biologics in Psoriatic Patients
Background: Psoriasis is a chronic immune-mediated inflammatory disease associated with systemic inflammation and an increased risk of cardiovascular events. Areas of Uncertainty: Although biologic therapies have transformed psoriasis tr...
05
DOI 10.1097/mjt.0000000000002252
Open DOI
Suspected Rosuvastatin-Associated Bullous Pemphigoid: A Diagnostic and Therapeutic Challenge
Was not provided for this article.
06
DOI 10.1097/mjt.0000000000002245
Open DOI
The Evolving Landscape of Hypertrophic Cardiomyopathy Treatment: Are Guidelines Keeping Pace?
Background: Hypertrophic cardiomyopathy (HCM) is a common inherited cardiovascular disorder associated with morbidity. Rapid advances in therapeutics—particularly the emergence of cardiac myosin inhibitors (CMIs)—suggest that current man...
07
DOI 10.1097/mjt.0000000000002240
Open DOI
Food, Dietary Supplement, and Gut Microbiome Interactions in Oral Anticancer Therapy: Mechanisms, Clinical Consequences, and Management
Background: The shift toward oral targeted therapies and immune checkpoint inhibitors (ICIs) in oncology has introduced pharmacokinetic variability driven by food–drug interactions (FDIs), which can cause therapeutic failure or increased...
08
DOI 10.1097/mjt.0000000000002249
Open DOI
Janus Kinase Inhibitors for Treatment of Morphea: Report of Two Cases and a Literature Review
Was not provided for this article.
09
DOI 10.1097/mjt.0000000000002128
Open DOI
Management of Upadacitinib-Induced Anemia in a Patient With Ulcerative Colitis
Was not provided for this article.
10
DOI 10.1097/mjt.0000000000002000
Open DOI
Tofacitinib for Hydroxychloroquine-Resistant Reticular Erythematous Mucinosis
Bibliographical & Catalog Notes
Title from cover.
Print issues ceased with v. 19 (2012).
Also issued online.